Natural history of infantileâ€onset spinal muscular atr

Annals of Neurology
82, 883-891
DOI: 10.1002/ana.25101

Citation Report

#	Article	IF	Citations
1	Building on NeuroNEXT: Next generation clinics to cure chronic neurological disability. Annals of Neurology, 2017, 82, 859-862.	2.8	1
2	NeuroNEXT is at your service. Annals of Neurology, 2017, 82, 857-858.	2.8	2
3	New and developing therapies in spinal muscular atrophy. Paediatric Respiratory Reviews, 2018, 28, 3-10.	1.2	15
4	A prospective natural history study of type 1 spinal muscular atrophy. Nature Reviews Neurology, 2018, 14, 197-198.	4.9	4
5	Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy. Molecular Neurobiology, 2018, 55, 6307-6318.	1.9	53
7	Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease. Journal of Managed Care & Specialty Pharmacy, 2018, 24, S3-S16.	0.5	34
8	Multiplex Droplet Digital PCR Method Applicable to Newborn Screening, Carrier Status, and Assessment of Spinal Muscular Atrophy. Clinical Chemistry, 2018, 64, 1753-1761.	1.5	45
9	Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study. Journal of Neuromuscular Diseases, 2018, 5, 509-521.	1.1	12
10	New Directions for SMA Therapy. Journal of Clinical Medicine, 2018, 7, 251.	1.0	25
11	Spinal muscular atrophy within Amish and Mennonite populations: Ancestral haplotypes and natural history. PLoS ONE, 2018, 13, e0202104.	1.1	6
12	Prenatal aspects in spinal muscular atrophy: From early detection to early presymptomatic intervention. European Journal of Paediatric Neurology, 2018, 22, 944-950.	0.7	20
13	Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy. Journal of Pediatric Orthopaedics, 2018, 38, e610-e617.	0.6	44
14	Nusinersen in patients older than 7 months with spinal muscular atrophy type 1. Neurology, 2018, 91, e1312-e1318.	1.5	91
15	An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology, 2018, 91, e696-e703.	1.5	24
16	Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany. Journal of Neuromuscular Diseases, 2018, 5, 135-143.	1.1	97
17	Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!. Contemporary Clinical Trials Communications, 2018, 11, 113-119.	0.5	11
18	Gene therapy for neurological disorders: progress and prospects. Nature Reviews Drug Discovery, 2018, 17, 641-659.	21.5	222
19	Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. Neuromuscular Disorders, 2018, 28, 582-585.	0.3	67

#	Article	IF	Citations
20	AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. Journal of Neuromuscular Diseases, 2019, 6, 307-317.	1.1	124
21	Spinal Muscular Atrophy (SMA) in the Therapeutic Era. Current Genetic Medicine Reports, 2019, 7, 162-167.	1.9	2
22	Neuromuscular Diseases of the Newborn. Seminars in Pediatric Neurology, 2019, 32, 100771.	1.0	6
23	Treating neonatal spinal muscular atrophy: A 21st century success story?. Early Human Development, 2019, 138, 104851.	0.8	11
24	One Year of Newborn Screening for SMA â€“ Results of a German Pilot Project. Journal of Neuromuscular Diseases, 2019, 6, 503-515.	1.1	105
25	Development of an academic disease registry for spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 794-799.	0.3	29
26	Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1547-1550.	2.5	34
27	Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Frontiers in Neurology, 2019, 10, 898.	1.1	49
28	Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy. Neurology, 2019, 93, e653-e664.	1.5	24
29	Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disorders, 2019, 29, 842-856.	0.3	401
30	Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, GuÃ©rin A, et al. Adv Ther (2019) 36(5):1164â€“76. doi:10.1007/s12325-019-00923-8. Advances in Therapy, 2019, 36, 2979-2981.	1.3	5
31	Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, GuÃ©rin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. Advances in Therapy, 2019, 36, 2982-2985.	1.3	0
32	Novel challenges in spinal muscular atrophy â€“ How to screen and whom to treat?. Annals of Clinical and Translational Neurology, 2019, 6, 197-205.	1.7	30
33	Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984605.	1.5	41
34	Nusinersen in type 1 spinal muscular atrophy: Twelveâ€month realâ€world data. Annals of Neurology, 2019, 86, 443-451.	2.8	83
35	Genetic approaches to the treatment of inherited neuromuscular diseases. Human Molecular Genetics, 2019, 28, R55-R64.	1.4	23
36	Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Journal of Market Access & Health Policy, 2019, 7, 1601484.	0.8	62
37	Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatric Neurology, 2019, 98, 39-45.	1.0	128

#	Article	IF	Citations
38	Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. European Journal of Human Genetics, 2019, 27, 1774-1782.	1.4	26
39	Neurofilament as a potential biomarker for spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2019, 6, 932-944.	1.7	137
40	Current Treatment Options in Neurologyâ€"SMA Therapeutics. Current Treatment Options in Neurology, 2019, 21, 25.	0.7	47
41	Nusinersen in later-onset spinal muscular atrophy. Neurology, 2019, 92, e2492-e2506.	1.5	183
42	Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Advances in Therapy, 2019, 36, 1164-1176.	1.3	68
43	Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry. Frontiers in Genetics, 2019, 10, 1255.	1.1	20
44	A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy. Neurology: Clinical Practice, 2019, 9, 424-432.	0.8	8
46	Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care. Neurological Sciences, 2019, 40, 327-332.	0.9	18
47	Health outcomes in spinal muscular atrophy type 1 following AVXSâ€101 gene replacement therapy. Pediatric Pulmonology, 2019, 54, 179-185.	1.0	142
48	Gene Replacement Therapy: A Primer for the Health-system Pharmacist. Journal of Pharmacy Practice, 2020, 33, 846-855.	0.5	28
49	Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy. Muscle and Nerve, 2020, 61, 187-191.	1.0	18
50	Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Developmental Medicine and Child Neurology, 2020, 62, 310-314.	1.1	36
51	Reply to Chacko et al.: Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 624-626.	2.5	1
52	Spinal muscular atrophy â€" insights and challenges in the treatment era. Nature Reviews Neurology, 2020, 16, 706-715.	4.9	89
53	Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients. Neuromuscular Disorders, 2020, 30, 693-700.	0.3	10
54	Clinical Reasoning: A 12-month-old child with hypotonia and developmental delays. Neurology, 2020, 95, 184-187.	1.5	5
55	New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. Journal of Clinical Medicine, 2020, 9, 2222.	1.0	96
56	Sobrecarga del cuidador de pacientes con atrofia muscular espinal. Revista MÃ©dica ClÃ¬nica Las Condes, 2020, 31, 358-366.	0.2	2

#	Article	IF	Citations
57	The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment. Journal of Personalized Medicine, 2020, 10, 75.	1.1	26
58	Spinal Muscular Atrophy in the Treatment Era. Neurologic Clinics, 2020, 38, 505-518.	0.8	19
59	Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience. Paediatric Respiratory Reviews, 2021, 39, 54-60.	1.2	16
60	Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations. Canadian Journal of Neurological Sciences, 2021, 48, 504-511.	0.3	18
61	Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. Pediatrics, 2020, 146, .	1.0	82
62	Stander Use in Spinal Muscular Atrophy: Results From a Large Natural History Database. Pediatric Physical Therapy, 2020, 32, 235-241.	0.3	8
63	Spinal muscular atrophy â€" challenges in the therapeutic era. Nature Reviews Neurology, 2020, 16, 655-656.	4.9	1
64	The Burden of Spinal Muscular Atrophy on Informal Caregivers. International Journal of Environmental Research and Public Health, 2020, 17, 8989.	1.2	20
65	Motor unit number index in children with laterâ€onset spinal muscular atrophy. Muscle and Nerve, 2020, 62, 633-637.	1.0	9
66	New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?. International Journal of Molecular Sciences, 2020, 21, 3297.	1.8	67
67	Defining the effect of medical treatment on respiratory needs in patients with Type 1 spinal muscular atrophy. Journal of Pediatrics, 2020, 223, 227.	0.9	0
68	Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1. Journal of Pediatrics, 2020, 225, 252-258.e1.	0.9	79
69	Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet Journal of Rare Diseases, 2020, 15, 148.	1.2	63
70	RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design. Journal of Neuromuscular Diseases, 2020, 7, 145-152.	1.1	17
71	Diagnostic Testing for Patients with Spinal Muscular Atrophy. Clinics in Laboratory Medicine, 2020, 40, 357-367.	0.7	2
72	Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy TreatedÂwith Nusinersen. Journal of Pediatrics, 2020, 219, 223-228.e4.	0.9	51
73	Assessment of motor unit loss in patients with spinal muscular atrophy. Clinical Neurophysiology, 2020, 131, 1280-1286.	0.7	23
74	RNA-Targeted Therapies and High-Throughput Screening Methods. International Journal of Molecular Sciences, 2020, 21, 2996.	1.8	24

#	Article	IF	Citations
75	Natural history of lung function in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2020, 15, 88.	1.2	56
76	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	4.5	6
77	Choosing Life with Spinal Muscular Atrophy Type 1. Advances in Therapy, 2020, 37, 1708-1713.	1.3	0
78	Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet Journal of Rare Diseases, 2020, 15, 84.	1.2	45
79	Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study. Neurology, 2021, 96, e587-e599.	1.5	36
80	Carrier frequency of <scp>SMN1</scp>â€related spinal muscular atrophy in north Indian population: The need for population based screening program. American Journal of Medical Genetics, Part A, 2021, 185, 274-277.	0.7	7
81	Respiratory outcomes post nusinersen in spinal muscular atrophy type 1. Pediatric Pulmonology, 2021, 56, 807-808.	1.0	2
82	Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen. Pediatric Pulmonology, 2021, 56, 299-306.	1.0	26
83	The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy. Journal of Neuromuscular Diseases, 2021, 8, 109-123.	1.1	9
84	Natural history in spinal muscular atrophy Type I in Taiwanese population: A longitudinal study. Brain and Development, 2021, 43, 127-134.	0.6	10
85	Nusinersen for spinal muscular atrophy type 1: Realâ€world respiratory experience. Pediatric Pulmonology, 2021, 56, 291-298.	1.0	36
86	Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. , 2021, 220, 107719.		60
87	Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatric Pulmonology, 2021, 56, 710-720.	1.0	31
88	Graphical Analyses in the Regulatory Evaluation of Gene Therapy Applications. Therapeutic Innovation and Regulatory Science, 2021, 55, 346-359.	0.8	2
89	Update on Biomarkers in Spinal Muscular Atrophy. Biomarker Insights, 2021, 16, 117727192110356.	1.0	27
90	Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet Journal of Rare Diseases, 2021, 16, 47.	1.2	54
91	An updated cost-utility model for onasemnogene abeparvovec (ZolgensmaÂ®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). Journal of Market Access & Health Policy, 2021, 9, 1889841.	0.8	27
92	Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Science Translational Medicine, 2021, 13, .	5.8	56

#	Article	IF	Citations
93	Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1244-1246.	0.9	12
94	In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy. Brain Sciences, 2021, 11, 194.	1.1	19
95	Costs of Illness of Spinal Muscular Atrophy: A Systematic Review. Applied Health Economics and Health Policy, 2021, 19, 501-520.	1.0	16
96	Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1. Journal of Neurodevelopmental Disorders, 2021, 13, 9.	1.5	15
97	Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A crossâ€sectional study. Journal of Cellular and Molecular Medicine, 2021, 25, 3765-3771.	1.6	10
98	Consensus on gene replacement therapy for spinal muscular atrophy. L O Badalyan Neurological Journal, 2021, 2, 7-9.	0.1	1
99	Risdiplam in Type 1 Spinal Muscular Atrophy. New England Journal of Medicine, 2021, 384, 915-923.	13.9	229
100	Decoding gene therapy: Current impact and future considerations for health-system and specialty pharmacy practice. American Journal of Health-System Pharmacy, 2021, 78, 953-961.	0.5	1
101	Hereditary Myelopathies. Seminars in Neurology, 2021, 41, 303-308.	0.5	2
102	Nusinersen treatment of older children and adults with spinal muscular atrophy. Neuromuscular Disorders, 2021, 31, 183-193.	0.3	17
103	Infantile spinal muscular atrophy â€" the potential for cure of a fatal disease. Journal of Neonatal-Perinatal Medicine, 2021, 14, 153-157.	0.4	1
104	Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen. Journal of Neuromuscular Diseases, 2021, 8, 217-224.	1.1	12
105	Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology, The, 2021, 20, 284-293.	4.9	227
106	Spinal Muscular Atrophy. Seminars in Pediatric Neurology, 2021, 37, 100878.	1.0	35
107	Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen. Neuromuscular Disorders, 2021, 31, 310-318.	0.3	10
108	Electromyography in infants: experience from a pediatric neuromuscular center. Acta Neurologica Belgica, 2022, 122, 1195-1200.	0.5	2
109	Functional movement assessment with the Test of Infant Motor Performance. Journal of Perinatology, 2021, 41, 2385-2394.	0.9	7
110	Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA). BMC Pediatrics, 2021, 21, 236.	0.7	4

#	Article	IF	Citations
111	Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies. Translational Neurodegeneration, 2021, 10, 16.	3.6	39
112	Prognostic Factors and Treatmentâ€Effect Modifiers in Spinal Muscular Atrophy. Clinical Pharmacology and Therapeutics, 2021, 110, 1435-1454.	2.3	7
113	Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada. Journal of Neuromuscular Diseases, 2021, 8, 553-568.	1.1	30
114	Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. The Lancet Child and Adolescent Health, 2021, 5, 491-500.	2.7	47
115	Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurology, 2021, 78, 834.	4.5	135
116	Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. New England Journal of Medicine, 2021, 385, 427-435.	13.9	137
117	Clinical outcome assessments in Duchenne muscular dystrophy and spinal muscular atrophy: past, present and future. Neuromuscular Disorders, 2021, 31, 1028-1037.	0.3	1
118	Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Current Medical Research and Opinion, 2021, 37, 1719-1730.	0.9	11
119	Sagittal Plane Deformities in Children with SMA2 following Posterior Spinal Instrumentation. Children, 2021, 8, 703.	0.6	1
120	Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies. Muscle and Nerve, 2021, 64, 641-650.	1.0	2
121	U7 snRNA, a Small RNA with a Big Impact in Gene Therapy. Human Gene Therapy, 2021, 32, 1317-1329.	1.4	5
122	Cerebrospinal Fluid and Clinical Profiles in Adult Type 2â€“3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience. Clinical Drug Investigation, 2021, 41, 775-784.	1.1	10
123	Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. BMJ Neurology Open, 2021, 3, e000164.	0.7	16
124	Views of the General Population on Newborn Screening for Spinal Muscular Atrophy in Japan. Children, 2021, 8, 694.	0.6	7
125	Retrospective analysis of the natural history of type 1 spinal muscular atrophy in children. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2021, 66, 64-73.	0.1	1
126	Advances in the Therapy of Spinal Muscular Atrophy. Journal of Pediatrics, 2021, 236, 13-20.e1.	0.9	6
127	Systematic Review of Motor Function Scales and Patient-Reported Outcomes in Spinal Muscular Atrophy. American Journal of Physical Medicine and Rehabilitation, 2022, 101, 590-608.	0.7	4
128	Paradigm shift in the era of disease-modifying therapies for Spinal Muscular Atrophy type 1: respiratory challenges and opportunities. Sleep Medicine, 2021, 86, 113-115.	0.8	1

#	Article	IF	Citations
129	Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology, The, 2021, 20, 832-841.	4.9	112
130	Electrical impedance tomography detects changes in ventilation after airway clearance in spinal muscular atrophy type I. Respiratory Physiology and Neurobiology, 2021, 294, 103773.	0.7	4
131	Nusinersen Treatment in Adults With Spinal Muscular Atrophy. Neurology: Clinical Practice, 2021, 11, e317-e327.	0.8	35
132	Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next. Annual Review of Genomics and Human Genetics, 2020, 21, 231-261.	2.5	134
133	Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. Journal of Clinical Investigation, 2018, 128, 3219-3227.	3.9	78
134	The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States. Orphanet Journal of Rare Diseases, 2020, 15, 118.	1.2	5
135	Population-based analysis of survival in spinal muscular atrophy. Neurology, 2020, 94, e1634-e1644.	1.5	54
136	Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy. Journal of Health Economics and Outcomes Research, 2019, 6, 185-195.	0.6	9
137	Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. Journal of Pediatric Pharmacology and Therapeutics, 2019, 24, 194-203.	0.3	72
138	Gene replacement therapy for spinal muscular atrophy unmasking occult hepatitis <scp>C</scp> in a pediatric patient. Muscle and Nerve, 2022, 65, E2.	1.0	0
139	1H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 441.	1.2	8
140	Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy. Muscle and Nerve, 2022, 65, 51-59.	1.0	8
141	Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet Journal of Rare Diseases, 2021, 16, 430.	1.2	58
142	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Scientific Reports, 2021, 11, 19922.	1.6	32
143	Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nature Medicine, 2021, 27, 1701-1711.	15.2	49
144	Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy. Frontiers in Neurology, 2021, 12, 726468.	1.1	12
145	Spinal Muscular Atrophy/Lambert Eaton Myasthenic Syndrome. , 2020, , 151-158.		0
146	Identification of a Novel Class of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screening. RSC Drug Discovery Series, 2020, , 140-159.	0.2	0

#	Article	IF	Citations
147	Spinal muscular atrophy (SMA) type I (Werdnig-Hoffmann disease). Archives De Pediatrie, 2020, 27, 7S15-7S17.	0.4	6
148	Rehabilitation of spinal muscular atrophy: current consensus and future direction. Journal of Genetic Medicine, 2020, 17, 55-61.	0.1	3
149	Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease). Archives De Pediatrie, 2020, 27, 7S23-7S28.	0.4	10
150	Optimizing Rare Disease Registries and Natural History Studies. , 2021, , 109-125.		0
151	Spinal muscular atrophy. , 2020, , 377-395.		0
152	An evaluation of onasemnogene abeparvovec for Spinal Muscular Atrophy (SMN1). Expert Opinion on Orphan Drugs, 0, , .	0.5	0
153	Spinal Muscular Atrophy: Huge Steps. Cerebrum: the Dana Forum on Brain Science, 2019, 2019, .	0.1	0
154	25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy. Acta Myologica, 2020, 39, 336-344.	1.5	0
155	Hypotonia. , 2021, , .		0
156	Prevalence, Incidence, and Risk of Progression of Asymptomatic Pancreatic Cysts in Large Sample Real-world Data. Pancreas, 2021, 50, 1287-1292.	0.5	17
157	Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen. Journal of Neuromuscular Diseases, 2022, 9, 111-119.	1.1	16
158	Genetic architecture of motor neuron diseases. Journal of the Neurological Sciences, 2022, 434, 120099.	0.3	7
159	Newborn Screening. , 2021, , .		0
160	Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy. Brain and Development, 2022, 44, 287-293.	0.6	10
161	Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model. CNS Drugs, 2022, 36, 181-190.	2.7	6
162	Body mass index in type 2 spinal muscular atrophy: a longitudinal study. European Journal of Pediatrics, 2022, , 1.	1.3	2
163	Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen. Developmental Medicine and Child Neurology, 2022, 64, 907-914.	1.1	17
164	Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Neuromuscular Disorders, 2022, 32, 399-409.	0.3	12

#	Article	IF	Citations
165	Cribado neonatal en atrofia muscular espinal: un desafÃo para cambiar la historia natural. Revista Del Hospital Italiano De Buenos Aires, 2021, 41, 71-8.	0.0	0
166	Body of Evidence for Onasemnogene Abeparvovec in Spinal Muscular Atrophy Supports Long-Term Duration of Effect Without Relapse. Value in Health, 2022, , .	0.1	0
167	Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). Expert Opinion on Investigational Drugs, 2022, 31, 451-461.	1.9	17
168	Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen. Pediatric Pulmonology, 2022, 57, 1505-1512.	1.0	5
169	Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys. Human Gene Therapy, 2022, 33, 740-756.	1.4	21
170	Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls. Neurology and Therapy, 2022, 11, 449-457.	1.4	3
171	Spinal Muscular Atrophy 5q under the Mask of Myopathy: 10 Clinical Cases. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2021, 20, 576-580.	0.1	0
172	Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. Expert Opinion on Biological Therapy, 2022, 22, 1075-1090.	1.4	13
177	Natural history of spinal muscular atrophy in children: an analysis of 117 cases. Chinese Journal of Contemporary Pediatrics, 2021, 23, 1038-1043.	0.2	1
178	Rapid Molecular Diagnosis of Genetically Inherited Neuromuscular Disorders Using Next-Generation Sequencing Technologies. Journal of Clinical Medicine, 2022, 11, 2750.	1.0	3
179	Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program. Pediatric Neurology, 2022, 132, 27-32.	1.0	13
181	Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era. Neurology: Clinical Practice, 2022, 12, 279-287.	0.8	11
182	Spinal MÃ¼skÃ¼ler Atrofiâ€™li Ã‡ocuk HastanÄ±n Henderson HemÅŸirelik Modeline GÃ¶re DeÄŸerlendirilmesi. Adnan Menderes Ãœniversitesi SaÄŸlÄ±k Bilimleri FakÃ¼ltesi Dergisi, 2022, 6, 345-353.	0.4	1
183	Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence. Drug Design, Development and Therapy, 0, Volume 16, 1865-1883.	2.0	14
184	Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nature Medicine, 2022, 28, 1381-1389.	15.2	99
185	Multifarious plant compounds and their protective efficacy in the treatment of spinal muscular atrophy. , 2022, , 89-100.		0
186	CaracterizaciÃ³n clÃnica y funcional de pacientes con atrofia muscular espinal en el centro-occidente colombiano. Biomedica, 2022, 42, 89-99.	0.3	2
187	Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	7

#	Article	IF	Citations
188	Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain, 2023, 146, 668-677.	3.7	16
190	Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands. Value in Health, 2022, 25, 1696-1704.	0.1	13
191	Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies. Paediatric Drugs, 2022, 24, 585-602.	1.3	4
192	Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia. Journal of Neurology, 2022, 269, 6544-6554.	1.8	5
193	Trial by â€œFirstsâ€• Clinical Trial Design and Regulatory Considerations in the Development and Approval of the First AAV Gene Therapy Product in the United States. Cold Spring Harbor Perspectives in Medicine, 0, , a041312.	2.9	2
194	Georgia state spinal muscular atrophy newborn screening experience: Screening assay performance and early clinical outcomes. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 187-196.	0.7	7
195	Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis. Human Gene Therapy, 2023, 34, 129-138.	1.4	9
196	Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen. Pediatric Pulmonology, 2023, 58, 161-170.	1.0	3
197	Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurology, The, 2022, 21, 1110-1119.	4.9	34
198	CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy. Neurotherapeutics, 2023, 20, 245-253.	2.1	3
199	Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study. Brain Communications, 2022, 4, .	1.5	9
200	Suppression and Replacement Gene Therapy for KCNH2 -Mediated Arrhythmias. Circulation Genomic and Precision Medicine, 2022, 15, .	1.6	2
201	Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec. Sleep Medicine, 2023, 101, 234-237.	0.8	7
202	Significant healthcare burden and life cost of spinal muscular atrophy: real-world data. European Journal of Health Economics, 2023, 24, 1373-1382.	1.4	2
203	A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy. Pediatric Pulmonology, 2023, 58, 1004-1011.	1.0	5
204	Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies. Neurology, 2023, 100, 522-528.	1.5	4
205	Comprehensive profile and natural history of pediatric patients with spinal muscular atrophy: A large retrospective study from China. Frontiers in Neurology, 0, 13, .	1.1	1
206	Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs. Frontiers in Neurology, 0, 13, .	1.1	1

#	Article	IF	Citations
207	Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Advances in Therapy, 2023, 40, 903-919.	1.3	3
208	Mass spectrometry for metabolomics analysis: Applications in neonatal and cancer screening. Mass Spectrometry Reviews, 0, , .	2.8	4
209	Risdiplam as an orphan drug treatment of spinal muscular atrophy in adults and children (2 months) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.5	0
210	Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. International Journal of Molecular Sciences, 2023, 24, 1130.	1.8	10
211	Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth. Molecular Genetics and Metabolism Reports, 2023, 35, 100973.	0.4	0
212	Evaluation of sputum cultures in children with spinal Muscular atrophy. Respiratory Medicine, 2023, 209, 107143.	1.3	2
214	A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy. Neuromuscular Disorders, 2023, 33, 309-314.	0.3	2
216	Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study. BMC Neurology, 2023, 23, .	0.8	11
217	Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy. Journal of Health Economics and Outcomes Research, 0, , 185-195.	0.6	0
218	Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond. Canadian Journal of Neurological Sciences, 2024, 51, 203-209.	0.3	1
219	Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 469-482.	0.7	1
220	Modern principles of therapy for patients with spinal muscular atrophy. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2023, 123, 34.	0.1	0
221	Base editing rescue of spinal muscular atrophy in cells and in mice. Science, 2023, 380, .	6.0	46
222	Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience. Pediatric Neurology, 2023, 144, 60-68.	1.0	4
223	New therapies for spinal muscular atrophy: where we stand and what is next. European Journal of Pediatrics, 2023, 182, 2935-2942.	1.3	7
224	Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment1. Journal of Neuromuscular Diseases, 2023, 10, 531-540.	1.1	4
226	The Use of Real-World Data to Support the Assessment of the Benefit and Risk of a Medicine to Treat Spinal Muscular Atrophy. , 2023, , 387-411.		0
249	Childhood spinal muscular atrophy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 43-58.	1.0	2

#	Article	IF	Citations
252	Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open, 0, , .	0.9	0
267	Common Monogenetic Conditions in Newborns. , 2024, , 690-698.		0